Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 1
2003 5
2004 2
2005 5
2006 3
2007 7
2008 10
2009 2
2010 6
2011 5
2012 6
2013 8
2014 7
2015 2
2016 8
2017 10
2018 5
2019 8
2020 5
2021 5
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Genomic Classification and Prognosis in Acute Myeloid Leukemia.
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Döhner K, Schlenk RF, Döhner H, Campbell PJ. Papaemmanuil E, et al. Among authors: paschka p. N Engl J Med. 2016 Jun 9;374(23):2209-2221. doi: 10.1056/NEJMoa1516192. N Engl J Med. 2016. PMID: 27276561 Free PMC article. Clinical Trial.
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
Döhner H, Weber D, Krzykalla J, Fiedler W, Wulf G, Salih H, Lübbert M, Kühn MWM, Schroeder T, Salwender H, Götze K, Westermann J, Fransecky L, Mayer K, Hertenstein B, Ringhoffer M, Tischler HJ, Machherndl-Spandl S, Schrade A, Paschka P, Gaidzik VI, Theis F, Thol F, Heuser M, Schlenk RF, Bullinger L, Saadati M, Benner A, Larson R, Stone R, Döhner K, Ganser A. Döhner H, et al. Among authors: paschka p. Blood Adv. 2022 Sep 27;6(18):5345-5355. doi: 10.1182/bloodadvances.2022007223. Blood Adv. 2022. PMID: 35486475 Free PMC article. Clinical Trial.
The genomic landscape of core-binding factor acute myeloid leukemias.
Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J, Radtke I, Chao JR, Walsh MP, Song G, Andersson AK, Dang J, Dong L, Liu Y, Huether R, Cai Z, Mulder H, Wu G, Edmonson M, Rusch M, Qu C, Li Y, Vadodaria B, Wang J, Hedlund E, Cao X, Yergeau D, Nakitandwe J, Pounds SB, Shurtleff S, Fulton RS, Fulton LL, Easton J, Parganas E, Pui CH, Rubnitz JE, Ding L, Mardis ER, Wilson RK, Gruber TA, Mullighan CG, Schlenk RF, Paschka P, Döhner K, Döhner H, Bullinger L, Zhang J, Klco JM, Downing JR. Faber ZJ, et al. Among authors: paschka p. Nat Genet. 2016 Dec;48(12):1551-1556. doi: 10.1038/ng.3709. Epub 2016 Oct 31. Nat Genet. 2016. PMID: 27798625 Free PMC article.
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Schmalbrock LK, Dolnik A, Cocciardi S, Sträng E, Theis F, Jahn N, Panina E, Blätte TJ, Herzig J, Skambraks S, Rücker FG, Gaidzik VI, Paschka P, Fiedler W, Salih HR, Wulf G, Schroeder T, Lübbert M, Schlenk RF, Thol F, Heuser M, Larson RA, Ganser A, Stunnenberg HG, Minucci S, Stone RM, Bloomfield CD, Döhner H, Döhner K, Bullinger L. Schmalbrock LK, et al. Among authors: paschka p. Blood. 2021 Jun 3;137(22):3093-3104. doi: 10.1182/blood.2020007626. Blood. 2021. PMID: 33598693 Free PMC article. Clinical Trial.
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens UM, Nachbaur D, Samra MA, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S, Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik VI, Saadati M, Benner A, Schlenk RF, Döhner K, Ganser A; German–Austrian AML Study Group. Döhner H, et al. Among authors: paschka p. Lancet Haematol. 2023 Jul;10(7):e495-e509. doi: 10.1016/S2352-3026(23)00089-3. Epub 2023 May 12. Lancet Haematol. 2023. PMID: 37187198 Clinical Trial.
[Acute myeloid leukemia].
Döhner K, Paschka P, Döhner H. Döhner K, et al. Among authors: paschka p. Internist (Berl). 2015 Apr;56(4):354-63. doi: 10.1007/s00108-014-3596-5. Internist (Berl). 2015. PMID: 25787321 German.
Intermediate-risk acute myeloid leukemia therapy: current and future.
Döhner K, Paschka P. Döhner K, et al. Among authors: paschka p. Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):34-43. doi: 10.1182/asheducation-2014.1.34. Epub 2014 Nov 18. Hematology Am Soc Hematol Educ Program. 2014. PMID: 25696832 Review.
Core binding factor acute myeloid leukemia.
Paschka P. Paschka P. Semin Oncol. 2008 Aug;35(4):410-7. doi: 10.1053/j.seminoncol.2008.04.011. Semin Oncol. 2008. PMID: 18692691 Review.
105 results